新辅助化疗在宫颈癌治疗中的疗效分析  被引量:27

Effect of Neoadjuvant Chemotherapy on Cervical Cancer

在线阅读下载全文

作  者:宋红林[1] 黄清华[2] 李力[1] 

机构地区:[1]广西医科大学肿瘤医院妇瘤科,南宁市530021 [2]广西医科大学肿瘤医院,在读研究生南宁市530021

出  处:《中国肿瘤临床》2010年第24期1471-1475,共5页Chinese Journal of Clinical Oncology

摘  要:目的:探讨新辅助化疗在宫颈癌临床治疗中的作用。方法:以170例宫颈癌病例(Ⅰb~Ⅳ期)为新辅助化疗试验组,同期同条件未经新辅助化疗的160例病例为对照组进行回顾性分析。按其治疗方法将研究病例分为6组,两两配对:NS组(新辅助化疗+手术)与S组(单纯手术);NSR组(新辅助化疗+手术+放疗)与SR组(单纯手术+放疗);NR组(新辅助化疗+放疗)与R组(单纯放疗);进行配对组间比较。结果:新辅助化疗的总有效率为70%。NS组的1、3及5年生存率分别为87%、81%和81%;对照S组的为97%、93%和93%(P均>0.05);两组生存曲线无显著性差异(P=0.685)。NSR组的1、3及5年生存率分别为100%、93%和93%;对照SR组的为100%、100%和92%(P均>0.05);两组生存曲线无显著性差异(P=0.351)。NR组的1、3及5年生存率分别为76%、45%和36%;对照R组的为81%、54%和37%(P均>0.05);两组生存曲线无显著性差异(P=0.723)。各组新辅助化疗的不良反应以胃肠道反应为主,患者均可耐受。结论:在宫颈癌治疗中,新辅助化疗虽然不能显著提高宫颈癌患者的生存率,但仍是一种安全的、有较好近期疗效的治疗方法。Objective: To evaluate the efficacy and toxicity of neoadjuvant chemotherapy for cervical cancer. Methods: From 1985 to 2006, 330 patients with stage Ib-IV cervical cancers were managed into six groups (three pairs). Pair one: NS (NACT followed by surgery) compared with S (Surgery alone); Pair two: NSR (NACT followed by surgery and adjuvant radiotherapy) compared with SR (Surgery followed by adjuvant radiotherapy); Pair three: NR (NACT followed by radical radiotherapy) compared to R (Radical radiotherapy alone). Results: Overall effective rate of NACT was 70%. Pair one: The patient survival rates at 1, 3, and 5 years were 87%,81%, and 81% (NS) versus 97%, 93% and 93%(S), respectively (P 〉 0.05). Pair two: The patient survival rates at 1, 3, and 5 years were 100%, 93%, and 93% (NSR) versus 100%, 100% and 92% (SR), respectively (P 〉 0.05). Pair three: The patient survival rates at 1, 3, and 5 years were 76%, 45%, and 36% (NR) versus 81%, 54% and 34% (R), respectively (P 〉 0.05). No significant differences were found in survival curves among these three pairs. The most common adverse reactions were gastrointestinal reactions. Conclusion: NACT is effective for cervical cancer but with no benefit for overall survival.

关 键 词:宫颈癌 新辅助化疗 生存率 

分 类 号:R737.33[医药卫生—肿瘤]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象